Biomea Fusion BMF-650 Phase 1 Weight Loss Results Remain Preliminary, With Longer-Term Trials And Toxicology Studies Still Outstanding
Safety and TolerabilityAcross the five active-dose MAD cohorts (n=40), all reported treatment-emergent adverse events (TEAEs) were mild or moderate. There were no severe or serious TEAEs, TEAE-related dose
Biomea's weight loss drug looks safe in early tests so far. The company still needs to run bigger studies before we know if it really works.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.